Large Scale Prediction and Testing of Drug Activity on Side-Effect Targets
暂无分享,去创建一个
Michael J. Keiser | B. Shoichet | J. Jenkins | D. Mikhailov | Eugen Lounkine | S. Whitebread | J. Hamon | P. Lavan | E. Weber | Allison K. Doak | S. Côté | L. Urban | Paul Lavan
[1] K. Beaumont,et al. Muscimol binding in rat brain: Association with synaptic GABA receptors , 1978, Brain Research.
[2] D. Hoyer,et al. [125I]BE 2254, a new high affinity radioligand for alpha 1-adrenoceptors. , 1981, European journal of pharmacology.
[3] J. Leysen,et al. [3H]Ketanserin (R 41 468), a selective 3H-ligand for serotonin2 receptor binding sites. Binding properties, brain distribution, and functional role. , 1982, Molecular pharmacology.
[4] D. Hoyer,et al. Molecular pharmacology of 5-HT1 and 5-HT2 recognition sites in rat and pig brain membranes: radioligand binding studies with [3H]5-HT, [3H]8-OH-DPAT, (-)[125I]iodocyanopindolol, [3H]mesulergine and [3H]ketanserin. , 1985, European journal of pharmacology.
[5] R. Ransom,et al. Cooperative Modulation of [3H]MK‐801 Binding to the N‐Methyl‐d‐Aspartate Receptor‐Ion Channel Complex by l‐Glutamate, Glycine, and Polyamines , 1988, Journal of neurochemistry.
[6] E. Liu,et al. Characterization of [5,6-3H]SQ 29,548 as a high affinity radioligand, binding to thromboxane A2/prostaglandin H2-receptors in human platelets. , 1988, The Journal of pharmacology and experimental therapeutics.
[7] R. Schoen,et al. Mechanisms of nonsteroidal anti-inflammatory drug-induced gastric damage. , 1989, The American journal of medicine.
[8] J. Bonnar,et al. Effect of Oestrogen Dose on Whole Blood Platelet Activation in Women Taking New Low Dose Oral Contraceptives , 1994, Thrombosis and Haemostasis.
[9] M. Scheinin,et al. Recombinant human alpha 2-adrenoceptor subtypes: comparison of [3H]rauwolscine, [3H]atipamezole and [3H]RX821002 as radioligands. , 1995, Biochimica et biophysica acta.
[10] E. Green,et al. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome , 1995, Cell.
[11] A. Brown,et al. HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. , 1996, Circulation.
[12] B Testa,et al. Binding of arylpiperazines, (aryloxy)propanolamines, and tetrahydropyridylindoles to the 5-HT1A receptor: contribution of the molecular lipophilicity potential to three-dimensional quantitative structure-affinity relationship models. , 1996, Journal of medicinal chemistry.
[13] Thomas L. Madden,et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. , 1997, Nucleic acids research.
[14] S. Z. Zhao,et al. Prevalence and cost of hospitalization for gastrointestinal complications related to peptic ulcers with bleeding or perforation: comparison of two national databases. , 1998, The American journal of managed care.
[15] E. Brown,et al. The Medical Dictionary for Regulatory Activities (MedDRA) , 1999, Drug safety.
[16] B. Lou,et al. Inhibition of Na(+) current by diphenhydramine and other diphenyl compounds: molecular determinants of selective binding to the inactivated channels. , 2000, Molecular pharmacology.
[17] B. Roth,et al. Evidence for Possible Involvement of 5-HT2B Receptors in the Cardiac Valvulopathy Associated With Fenfluramine and Other Serotonergic Medications , 2000, Circulation.
[18] Daniela Gabriel,et al. High throughput screening technologies for direct cyclic AMP measurement. , 2003, Assay and drug development technologies.
[19] Yu Zong Chen,et al. Drug Adverse Reaction Target Database (DART) , 2003, Drug safety.
[20] S. Heller,et al. An Open Standard for Chemical Structure Representation: The IUPAC Chemical Identifier , 2003 .
[21] D. Grosset,et al. Role of dopamine transporter imaging in the diagnosis of atypical tremor disorders , 2003, Movement disorders : official journal of the Movement Disorder Society.
[22] Gary A Gintant,et al. The [3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K+]o. , 2004, Journal of pharmacological and toxicological methods.
[23] D. Hoyer,et al. Comparison of functional profiles at human recombinant somatostatin sst2 receptor: simultaneous determination of intracellular Ca2+ and luciferase expression in CHO‐K1 cells , 2004, British journal of pharmacology.
[24] Dairong Wang,et al. Cardiovascular hazard and non-steroidal anti-inflammatory drugs. , 2005, Current opinion in pharmacology.
[25] S. Urwyler,et al. SDZ GLC 756, a novel octahydrobenzo[g]quinoline derivative exerts opposing effects on dopamine D1 and D2 receptors , 2005, Journal of Neural Transmission.
[26] W. Siess,et al. Multiple electrode aggregometry: A new device to measure platelet aggregation in whole blood , 2006, Thrombosis and Haemostasis.
[27] G. V. Paolini,et al. Global mapping of pharmacological space , 2006, Nature Biotechnology.
[28] P. Akarasereenont,et al. The effects of estrone, estradiol and estriol on platelet aggregation induced by adrenaline and adenosine diphosphate , 2006, Platelets.
[29] Yi Wang,et al. DITOP: drug-induced toxicity related protein database , 2007, Bioinform..
[30] R. Krauss,et al. When good drugs go bad , 2007, Nature.
[31] P. Leeson,et al. The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.
[32] Jeremy R. Greenwood,et al. Epik: a software program for pKa prediction and protonation state generation for drug-like molecules , 2007, J. Comput. Aided Mol. Des..
[33] A. Barabasi,et al. Drug—target network , 2007, Nature Biotechnology.
[34] A. Bender,et al. Modeling Promiscuity Based on in vitro Safety Pharmacology Profiling Data , 2007, ChemMedChem.
[35] Michael J. Keiser,et al. Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.
[36] A. Bender,et al. Analysis of Pharmacology Data and the Prediction of Adverse Drug Reactions and Off‐Target Effects from Chemical Structure , 2007, ChemMedChem.
[37] Yvonne C. Martin,et al. Application of Belief Theory to Similarity Data Fusion for Use in Analog Searching and Lead Hopping , 2008, J. Chem. Inf. Model..
[38] R. Solé,et al. Data completeness—the Achilles heel of drug-target networks , 2008, Nature Biotechnology.
[39] A. Hopkins. Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.
[40] David S. Wishart,et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets , 2007, Nucleic Acids Res..
[41] Tudor I. Oprea,et al. Quantifying the Relationships among Drug Classes , 2008, J. Chem. Inf. Model..
[42] A. Wise,et al. Use of Cryopreserved Cells for Enabling Greater Flexibility in Compound Profiling , 2008, Journal of biomolecular screening.
[43] P. Bork,et al. Drug Target Identification Using Side-Effect Similarity , 2008, Science.
[44] R. Solé,et al. The topology of drug-target interaction networks: implicit dependence on drug properties and target families. , 2009, Molecular bioSystems.
[45] J. Peters,et al. Pharmacological Promiscuity: Dependence on Compound Properties and Target Specificity in a Set of Recent Roche Compounds , 2009, ChemMedChem.
[46] Scott Boyer. The Use of Computer Models in Pharmaceutical Safety Evaluation , 2009, Alternatives to laboratory animals : ATLA.
[47] Lin He,et al. SePreSA: a server for the prediction of populations susceptible to serious adverse drug reactions implementing the methodology of a chemical–protein interactome , 2009, Nucleic Acids Res..
[48] M. Milik,et al. Mapping adverse drug reactions in chemical space. , 2009, Journal of medicinal chemistry.
[49] Michael J. Keiser,et al. Predicting new molecular targets for known drugs , 2009, Nature.
[50] M. Perrone,et al. Selective COX-1 inhibition: A therapeutic target to be reconsidered. , 2010, Current medicinal chemistry.
[51] F. Beland,et al. Protein adducts as prospective biomarkers of nevirapine toxicity. , 2010, Chemical research in toxicology.
[52] P. Bork,et al. A side effect resource to capture phenotypic effects of drugs , 2010, Molecular systems biology.
[53] D. Mikhailov,et al. Cardiac ion channel safety profiling on the IonWorks Quattro automated patch clamp system. , 2010, Assay and drug development technologies.
[54] D. Lauffenburger,et al. Cytokine-associated drug toxicity in human hepatocytes is associated with signaling network dysregulation. , 2010, Molecular bioSystems.
[55] E. Matthews,et al. Prediction of drug-related cardiac adverse effects in humans--A: creation of a database of effects and identification of factors affecting their occurrence. , 2010, Regulatory toxicology and pharmacology : RTP.
[56] Yong Huang,et al. Kinase inhibition-related adverse events predicted from in vitro kinome and clinical trial data , 2010, J. Biomed. Informatics.
[57] David Rogers,et al. Extended-Connectivity Fingerprints , 2010, J. Chem. Inf. Model..
[58] María Martín,et al. Ongoing and future developments at the Universal Protein Resource , 2010, Nucleic Acids Res..
[59] Gideon Schreiber,et al. Protein binding specificity versus promiscuity. , 2010, Current opinion in structural biology.
[60] J. Arrowsmith. Trial watch: Phase II failures: 2008–2010 , 2011, Nature Reviews Drug Discovery.
[61] Bryan L. Roth,et al. Chemical Informatics and Target Identification in a Zebrafish Phenotypic Screen , 2011, Nature chemical biology.
[62] J. Arrowsmith. Trial watch: Phase III and submission failures: 2007–2010 , 2011, Nature Reviews Drug Discovery.
[63] Doheon Lee,et al. Building the process-drug–side effect network to discover the relationship between biological Processes and side effects , 2011, BMC Bioinformatics.
[64] R. Altman,et al. Detecting Drug Interactions From Adverse‐Event Reports: Interaction Between Paroxetine and Pravastatin Increases Blood Glucose Levels , 2011, Clinical pharmacology and therapeutics.
[65] Tudor I. Oprea,et al. Associating Drugs, Targets and Clinical Outcomes into an Integrated Network Affords a New Platform for Computer‐Aided Drug Repurposing , 2011, Molecular informatics.
[66] John P. Overington,et al. ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..
[67] Beau Dabbs,et al. Summary and discussion of : “ Controlling the False Discovery Rate : A Practical and Powerful Approach to Multiple Testing , 2014 .
[68] F. Segal,et al. A CHARACTERIZATION OF FIBRANT SEGAL CATEGORIES , 2006, math/0603400.